Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

This study compares a biosimilar version of semaglutide injection to the brand-name weight-loss medication Wegovy in Chinese adults with obesity, to see if they work equally well. Both are weekly injections that help reduce body weight, and all participants also receive diet and exercise counseling throughout the 48-week study. You may be eligible if you are 18 to 75 years old with a BMI of 28 or higher, have not had significant weight changes recently, and do not have a history of diabetes, pancreatitis, or certain other medical conditions. Participation involves weekly injections, regular clinic visits, and lifestyle counseling over nearly a year, followed by a 4-week safety check-in. This summary was prepared using AI to help patients understand this research.